APA (7th ed.) Citation

Popek-Marciniec, S., Styk, W., Wojcierowska-Litwin, M., Chocholska, S., Szudy-Szczyrek, A., Samardakiewicz, M., . . . Zmorzynski, S. (2023). Association of Chromosome 17 Aneuploidy, TP53 Deletion, Expression and Its rs1042522 Variant with Multiple Myeloma Risk and Response to Thalidomide/Bortezomib Treatment. Cancers, 15(19), 4747. https://doi.org/10.3390/cancers15194747

Chicago Style (17th ed.) Citation

Popek-Marciniec, Sylwia, Wojciech Styk, Magdalena Wojcierowska-Litwin, Sylwia Chocholska, Aneta Szudy-Szczyrek, Marzena Samardakiewicz, Grazyna Swiderska-Kolacz, Joanna Czerwik-Marcinkowska, and Szymon Zmorzynski. "Association of Chromosome 17 Aneuploidy, TP53 Deletion, Expression and Its Rs1042522 Variant with Multiple Myeloma Risk and Response to Thalidomide/Bortezomib Treatment." Cancers 15, no. 19 (2023): 4747. https://doi.org/10.3390/cancers15194747.

MLA (9th ed.) Citation

Popek-Marciniec, Sylwia, et al. "Association of Chromosome 17 Aneuploidy, TP53 Deletion, Expression and Its Rs1042522 Variant with Multiple Myeloma Risk and Response to Thalidomide/Bortezomib Treatment." Cancers, vol. 15, no. 19, 2023, p. 4747, https://doi.org/10.3390/cancers15194747.